An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Clinical trial NCT04130997 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04130997
- Sponsor
- TG Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-18
- Primary completion
- 2032-05-31
- Enrollment
- 1100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.